COMMUNIQUÉS West-GlobeNewswire

Motif Bio REVIVE-1 Phase 3 Study Results with Iclaprim Published in Peer-reviewed Journal, Clinical Infectious Diseases
21/12/2017
Iclaprim met the primary endpoint Iclaprim was well tolerated in the study Additional data from the previously announced topline results are included in the publication NEW YORK, Dec. 21, 2017 (GLOBE NEWSWIRE) -- Motif [...]
TRACON Pharmaceuticals and Ambrx Announce Development and Commercialization Agreement for TRC105 in China
21/12/2017
Initial Focus in China on Angiosarcoma and Hepatocellular Carcinoma Total Value of Deal up to $143.5 Million for TRACON, Including a $3 Million Upfront Payment and Potential Milestones, Plus Potential Tiered Royalties [...]
Zomedica Pharmaceuticals Corp. Enters into License and Supply Agreement with Celsee, Inc. for Cancer Liquid Biopsy Platform
21/12/2017
ANN ARBOR, Mich., Dec. 21, 2017 (GLOBE NEWSWIRE) -- Zomedica Pharmaceuticals Corp. (NYSE American:ZOM) (TSX-V: ZOM ) (“Zomedica” or “Company”), a veterinary pharmaceutical and diagnostic company, today announced it has [...]
DAXOR CORPORATION ANNOUNCES 2017 DIVIDEND
21/12/2017
New York, NY, Dec. 21, 2017 (GLOBE NEWSWIRE) -- Daxor Corporation, (NYSE MKT: DXR) an investment company with medical instrumentation and biotechnology operations, announced the payment of a dividend for 2017. The Board [...]
Histogenics Corporation and MEDINET Co., Ltd Enter Into Licensing Agreement for Development and Commercialization of NeoCart for the Japanese Market
21/12/2017
– Transaction Terms Include a $10 Million Up-front Payment with a Potential of $87 Million in Total Milestones, and Tiered Royalties on Sales ‒ ‒ Japanese Cartilage Repair Market is Large and Growing with Established [...]
Gemphire Therapeutics Announces Initiation of its First NASH Proof-of-Concept Clinical Trial and its Differentiated NASH Program
21/12/2017
Phase 2a trial will investigate gemcabene in Familial Partial Lipodystrophy (FPL) – a rare genetic disease with characteristic presentation of cardiovascular disease and NASH Gemcabene has a differentiated profile based [...]
Mesoblast Receives FDA Regenerative Medicine Advanced Therapy Designation for Its Cell Therapy in Heart Failure Patients With Left Ventricular Assist Devices
21/12/2017
NEW YORK and MELBOURNE, Australia, Dec. 21, 2017 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq: MESO ) (ASX:MSB) today announced that the United States Food and Drug Administration (FDA) has granted Regenerative [...]
Evergreen Receives Health Canada “Confirmation of Readiness to Inspect Letter” and Plans to Begin Construction of a Second Site and Building "A" of a Three Million sq ft Expansion Plan
21/12/2017
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES VICTORIA, British Columbia, Dec. 21, 2017 (GLOBE NEWSWIRE) -- EVERGREEN MEDICINAL SUPPLY INC. (“EVERGREEN” OR THE “COMPANY”) [...]
Zealand Pharma: Invitation to Capital Market Day in New York on 25 January, and event in Copenhagen on 29 January 2018
21/12/2017
Press release - No. 13/2017 Zealand Pharma: Invitation to Capital Market Day in New York on 25 January, and event in Copenhagen on 29 January 2018 Zealand's management will provide an update on strategy and business [...]
Latvijas Juras medicinas centrs JSC: Data of publication of financial reports in the year 2018.
21/12/2017
Latvia, 2017-12-21 08:47 CET (GLOBE NEWSWIRE) -- Latvijas Juras medicinas centrs JSC: Data of publication of financial reports in the year 2018: Consolidated not audited interim report for the 12 months of 2017 - 19.02. [...]
Summit Enters Licence and Commercialisation Agreement with Eurofarma for Latin American Rights to Ridinilazole
21/12/2017
Summit Therapeutics plc ("Summit" or the "Company") SUMMIT ENTERS INTO LICENCE AND COMMERCIALISATION AGREEMENT WITH EUROFARMA FOR LATIN AMERICAN RIGHTS TO RIDINILAZOLE, SUMMIT'S PRECISION ANTIBIOTIC IN DEVELOPMENT FOR [...]
Summit Enters Into Licence and Commercialisation Agreement With Eurofarma for Latin American Rights to Ridinilazole, Summit’s Precision Antibiotic in Development for the Treatment of CDI
21/12/2017
Summit to receive $2.5 million upfront payment Up to $25 million in development, regulatory, pricing and initial sales milestones Summit retains commercial rights to ridinilazole in rest of the world OXFORD, United [...]
Sales of Olainfarm in November Shrink by 10%
21/12/2017
Olaine, 2017-12-21 07:59 CET (GLOBE NEWSWIRE) -- November 2017, consolidated sales Sales, thsnd. EUR Changes to November 2016 Share in total sales Russia 3 563 -33% 35% Latvia 2 643 5% 26% Ukraine 1 542 209% 15% Belarus [...]
Basilea reports that ceftobiprole received QIDP designation from U.S. FDA for the treatment of Staphylococcus aureus bacteremia (SAB)
21/12/2017
Basel, Switzerland, December 21, 2017 - Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that the U.S. Food and Drug Administration (FDA) designated its investigational drug ceftobiprole as a Qualified Infectious [...]
ABLYNX ANNOUNCES POSITIVE DATA FROM ITS JAPANESE ETHNO-BRIDGING STUDY OF CAPLACIZUMAB
21/12/2017
Comparable pharmacokinetics (PK) observed in Japanese and Caucasian healthy volunteers Caplacizumab was well-tolerated in all groups GHENT, Belgium, 21 December 2017 - Ablynx NV [Euronext Brussels and Nasdaq: ABLX] [...]
Cannabis Wheaton Income Corp. Announces New Joint Venture for Development of World's Largest Indoor Cannabis Facility with Licensed Producer Partner FV Pharma Inc.
21/12/2017
VANCOUVER, British Columbia, Dec. 21, 2017 (GLOBE NEWSWIRE) -- Cannabis Wheaton Income Corp. (d/b/a Wheaton Income) (TSX.V:CBW) (" Wheaton Income " or "Wheaton" or the " Company ") is pleased to announce that it has [...]
Denali Therapeutics Announces Advancement and Expansion of Its LRRK2 Inhibitor Clinical Program for Parkinson’s Disease
20/12/2017
SOUTH SAN FRANCISCO, Calif., Dec. 20, 2017 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI ), a biopharmaceutical company developing a broad portfolio of therapeutic candidates for neurodegenerative diseases [...]
Apellis Finalizes Phase 3 Clinical Trial Plans for Geographic Atrophy Treatment with APL-2
20/12/2017
CRESTWOOD, Ky. and CAMBRIDGE, Ma., Dec. 20, 2017 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS ), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to [...]
Kraig Biocraft Laboratories posts Holiday Letter to Shareholders
20/12/2017
ANN ARBOR, Mich., Dec. 20, 2017 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB:KBLB) (“Company”), the leading developer of spider silk based fibers, announced that the Company posted a Letter to its [...]

Pages